Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Inventory (2016 - 2026)

Ocular Therapeutix has reported Change in Inventory over the past 13 years, most recently at $173000.0 for Q1 2026.

  • For Q1 2026, Change in Inventory fell 24.45% year-over-year to $173000.0; the TTM value through Mar 2026 reached $468000.0, down 32.66%, while the annual FY2025 figure was $524000.0, 28.71% down from the prior year.
  • Change in Inventory for Q1 2026 was $173000.0 at Ocular Therapeutix, up from $76000.0 in the prior quarter.
  • Over five years, Change in Inventory peaked at $635000.0 in Q4 2024 and troughed at -$230000.0 in Q2 2025.
  • A 5-year average of $146294.1 and a median of $108000.0 in 2022 define the central range for Change in Inventory.
  • Biggest five-year swings in Change in Inventory: soared 1432.14% in 2022 and later crashed 751.85% in 2025.
  • Year by year, Change in Inventory stood at $429000.0 in 2022, then tumbled by 88.81% to $48000.0 in 2023, then soared by 1222.92% to $635000.0 in 2024, then tumbled by 88.03% to $76000.0 in 2025, then skyrocketed by 127.63% to $173000.0 in 2026.
  • Business Quant data shows Change in Inventory for OCUL at $173000.0 in Q1 2026, $76000.0 in Q4 2025, and $449000.0 in Q3 2025.